Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Bought by Iron Triangle Partners LP

Iron Triangle Partners LP grew its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 13.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,200,036 shares of the company's stock after buying an additional 256,246 shares during the period. Teva Pharmaceutical Industries accounts for 5.3% of Iron Triangle Partners LP's portfolio, making the stock its 5th biggest position. Iron Triangle Partners LP owned approximately 0.19% of Teva Pharmaceutical Industries worth $48,489,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Diversify Advisory Services LLC lifted its position in shares of Teva Pharmaceutical Industries by 2.5% in the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock worth $426,000 after purchasing an additional 496 shares during the period. Thrivent Financial for Lutherans raised its position in shares of Teva Pharmaceutical Industries by 0.3% in the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock worth $4,964,000 after acquiring an additional 699 shares in the last quarter. Townsquare Capital LLC grew its stake in Teva Pharmaceutical Industries by 2.1% in the fourth quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock worth $885,000 after purchasing an additional 812 shares during the period. Metis Global Partners LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 6.7% during the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock valued at $302,000 after buying an additional 860 shares in the last quarter. Finally, Quadrant Capital Group LLC grew its holdings in Teva Pharmaceutical Industries by 27.7% in the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock worth $96,000 after purchasing an additional 949 shares during the period. Institutional investors own 54.05% of the company's stock.

Analyst Ratings Changes

Several equities analysts have issued reports on TEVA shares. Bank of America upped their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday, April 23rd. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Barclays dropped their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. Finally, JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $21.00 to $23.00 in a research report on Monday. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of "Buy" and an average price target of $24.43.

Teva Pharmaceutical Industries Stock Performance

TEVA traded down $0.44 during midday trading on Wednesday, hitting $17.05. 1,998,678 shares of the company were exchanged, compared to its average volume of 10,017,451. The company's 50 day simple moving average is $15.27 and its 200 day simple moving average is $17.44. The firm has a market capitalization of $19.33 billion, a price-to-earnings ratio of -11.77, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. The company had revenue of $3.89 billion for the quarter, compared to analysts' expectations of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The firm's quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.48 EPS. As a group, sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.